Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura

被引：102
作者：
Page, Evaren E. [1 ,2 ]
Hovinga, Johanna A. Kremer [3 ,4 ]
Terrell, Deirdra R. [1 ]
Vesely, Sara K. [1 ]
George, James N. [1 ,2 ]
机构：
[1] Univ Oklahoma, Hlth Sci Ctr, Coll Publ Hlth, Dept Biostat & Epidemiol, Oklahoma City, OK USA
[2] Univ Oklahoma, Hlth Sci Ctr, Coll Med, Dept Med,Hematol Oncol Sect, Oklahoma City, OK 73190 USA
[3] Univ Bern, Dept Hematol, Bern, Switzerland
[4] Univ Bern, Dept Clin Res, Univ Hosp Bern, Cent Hematol Lab, Bern, Switzerland
来源：
BLOOD | 2016年 / 127卷 / 24期
关键词：
EFFICACY; SAFETY;
D O I：
10.1182/blood-2016-03-703827
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：3092 / 3094
页数：3
相关论文
共 9 条
[1]   Rituximab in autoimmune thrombotic thrombocytopenic purpura: A success story [J].
Froissart, Antoine ;
Veyradier, Agnes ;
Hie, Miguel ;
Benhamou, Ygal ;
Coppo, Paul .
EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2015, 26 (09) :659-665
[2]   Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center [J].
Froissart, Antoine ;
Buffet, Marc ;
Veyradier, Agnes ;
Poullin, Pascale ;
Provot, Francois ;
Malot, Sandrine ;
Schwarzinger, Michael ;
Galicier, Lionel ;
Vanhille, Philippe ;
Vernant, Jean-Paul ;
Bordessoule, Dominique ;
Guidet, Bertrand ;
Azoulay, Elie ;
Mariotte, Eric ;
Rondeau, Eric ;
Mira, Jean-Paul ;
Wynckel, Alain ;
Clabault, Karine ;
Choukroun, Gabriel ;
Presne, Claire ;
Pourrat, Jacques ;
Hamidou, Mohamed ;
Coppo, Paul .
CRITICAL CARE MEDICINE, 2012, 40 (01) :104-111
[3]   Rituximab therapy for thrombotic thrombocytopenic purpura: A proposed study of the transfusion medicine/hemostasis clinical trials network with a systematic review of rituximab therapy for immune-mediated disorders [J].
George, JN ;
Woodson, RD ;
Kiss, JE ;
Kojouri, K ;
Vesely, SK .
JOURNAL OF CLINICAL APHERESIS, 2006, 21 (01) :49-56
[4]   Survival and relapse in patients with thrombotic thrombocytopenic purpura [J].
Hovinga, Johanna A. Kremer ;
Vesely, Sara K. ;
Terrell, Deirdra R. ;
Laemmle, Bernhard ;
George, James N. .
BLOOD, 2010, 115 (08) :1500-1511
[5]  
Kremer Hovinga JA, 2010, BLOOD, V115, P1662
[6]   The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura [J].
Lim, Wendy ;
Vesely, Sara K. ;
George, James N. .
BLOOD, 2015, 125 (10) :1526-1531
[7]   Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura [J].
Peyvandi, Flora ;
Scully, Marie ;
Hovinga, Johanna A. Kremer ;
Cataland, Spero ;
Knoebl, Paul ;
Wu, Haifeng ;
Artoni, Andrea ;
Westwood, John-Paul ;
Taleghani, Magnus Mansouri ;
Jilma, Bernd ;
Callewaert, Filip ;
Ulrichts, Hans ;
Duby, Christian ;
Tersago, Dominique .
NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (06) :511-522
[8]  
Pintilie M., 2006, COMPETING RISKS PRAC
[9]   A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura [J].
Scully, Marie ;
McDonald, Vickie ;
Cavenagh, Jamie ;
Hunt, Beverley J. ;
Longair, Ian ;
Cohen, Hannah ;
Machin, Samuel J. .
BLOOD, 2011, 118 (07) :1746-1753
1